15 terminated. 15 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis Rituximab, Infliximab, Tocilizumab - Giant Cell Arteritis, Takayasu Arteritis | Phase 2 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 22 | 2021-07-14 | 2025-06-17 |
| A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis Guselkumab, Placebo - Giant Cell Arteritis | Phase 2 | Terminated | Janssen Research & Development, LLC | 53 | 2020-12-10 | 2025-07-01 |
| A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Hemay005, Placebo - Behçet Disease | Phase 2 | Terminated | Tianjin Hemay Pharmaceutical Co., Ltd | 89 | 2020-11-30 | 2022-06-21 |
| Golimumab for the Treatment of Refractory Behcet's Uveitis Golimumab (GOL) - Behcet Syndrome, Uveitis | Phase 2 | Terminated | Wenjie Zheng | 1 | 2020-02-15 | 2023-04-07 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Tocilizumab for the Treatment of Refractory Behcet's Uveitis Tocilizumab (TCZ) - Behcet Syndrome, Uveitis | Phase 2 | Terminated | Wenjie Zheng | 3 | 2018-05-10 | 2021-03-22 |
| Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a PC-mAb, Placebo - Arterial Inflammation, Cardiovascular Diseases | Phase 2 | Terminated | Athera Biotechnologies AB | 10 | 2017-10-11 | 2018-07-06 |
| Ustekinumab for the Treatment of Giant Cell Arteritis Ustekinumab, Prednisone - Giant Cell Arteritis, Temporal Arteritis | Phase 1 / Phase 2 | Terminated | Massachusetts General Hospital | 13 | 2016-12-01 | 2020-06-12 |
| Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis rituximab, Prednisone, Placebo - Cryoglobulinemia, Systemic Vasculitis | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 14 | 2015-07-17 | 2019-03-18 |
| Tocilizumab for the Treatment of Behcet's Syndrome Tocilizumab - Behcet Syndrome | Phase 2 | Terminated | NYU Langone Health | 1 | 2012-09-01 | 2019-02-15 |
| Abatacept in ANCA Associated Vasculitis Abatacept (Orencia) - ANCA-associated Vasculitis | Phase 2 | Terminated | Imperial College London | 7 | 2007-11-01 | 2015-05-29 |
| Rituxan in Churg Strauss Syndrome With Renal Involvement Rituximab, Prednisone - Churg-Strauss Syndrome | Phase 2 | Terminated | Fernando Fervenza | 4 | 2007-06-01 | 2011-12-08 |
| A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Infliximab - Giant Cell Arteritis | Phase 2 | Terminated | Centocor, Inc. | 44 | 2003-11-01 | 2011-05-17 |
| Plasma Exchange for Renal Vasculitis Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis | Phase 2 / Phase 3 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 150 | 1995-03-01 | 2011-08-03 |
Behcet Syndrome (4) · Giant Cell Arteritis (4) · Granulomatosis with Polyangiitis (4) · Microscopic Polyangiitis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Churg-Strauss Syndrome (2) · Uveitis (2) · Arteritis (1) · Cardiovascular Diseases (1) · Cogan Syndrome (1) · Cryoglobulinemia (1) · Cryoglobulinemia, Familial Mixed (1) · Glomerulonephritis (1) · IgA Vasculitis (1)
Vascular Diseases (15) · Cardiovascular Diseases (14) · Skin Diseases (14) · Skin Diseases, Vascular (14) · Skin and Connective Tissue Diseases (14) · Immune System Diseases (10) · Autoimmune Diseases (9) · Brain Diseases (8) · Central Nervous System Diseases (8) · Cerebrovascular Disorders (8) · Nervous System Diseases (8) · Systemic Vasculitis (6) · Eye Diseases (5) · Arteritis (4)
Rituximab (4) · Prednisone (3) · tocilizumab (3) · Infliximab (2) · Abatacept (1) · Cyclic Nucleotide Phosphodiesterases, Type 4 (1) · Hemay005 (1) · Plasma Exchange (1) · Ustekinumab (1) · golimumab (1) · guselkumab (1) · obinutuzumab (1) · vilobelimab (1)
Cambridge University Hospitals NHS Foundation Trust (2) · Wenjie Zheng (2) · Assistance Publique - Hôpitaux de Paris (1) · Athera Biotechnologies AB (1) · Centocor, Inc. (1) · Fernando Fervenza (1) · Imperial College London (1) · InflaRx GmbH (1) · Janssen Research & Development, LLC (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · NYU Langone Health (1) · Tianjin Hemay Pharmaceutical Co., Ltd (1)
United States (6) · China (3) · United Kingdom (3) · Canada (2) · France (2) · Belgium (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Wenjie Zheng, M.D. (2) · Alan Salama (1) · David Jayne (1) · Eric SG Stroes, MD, Prof. (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Korinna Pilz, MD, MS (1) · Niels Rasmussen, MD (1) · Peter A. Merkel, MD, MPH (1) · Ulrich Specks, MD (1) · Yusuf Yazici, MD (1)
PMID 17470830, PMID 21325353, PMID 21873264, PMID 23615499, PMID 28528519, PMID 29471416, PMID 32248659, PMID 33164993, PMID 41748391
UL1RR024150 (1)